Emerging Technologies Live
image by imron from IMRON HAMSYAH's Images

Oncolytic Virus

Background

Oncolytic viruses are viruses that preferentially infect and kill cancer cells. These viruses have the potential to be used as a cancer therapy, either alone or in combination with other treatments. There is a growing body of evidence to support the use of oncolytic viruses in the clinic, and several clinical trials are currently underway.

Some of the emerging trends in Oncolytic Virus therapy include the use of genetically modified viruses to target specific cancer cells, the use of oncolytic viruses in combination with other cancer therapies, and the use of oncolytic viruses to deliver cancer-fighting genes to tumor cells.

See live data on companies, R&D, markets, and news

In order to access the link, you need a Mergeflow account.

No Mergeflow account yet?

No credit card, no software to install. Trial ends automatically after 14 days.

Teams and individuals from across industries and tech sectors use Mergeflow

Curious to see how it works?

Watch our free video course:

Frequently asked questions about the trial

After you sign up, you’ll receive an email from us with an account activation link. Over the course of the trial, we’ll send you emails with tips and tricks. The trial ends automatically after 14 days. No further obligations on your part.

No. We do not ask for your credit card up front, so you will only be charged when you decide to buy a subscription.

No. Mergeflow is a SaaS software that runs in any modern web browser. And because it’s a subscription, you get constant product updates.

You can pay your Innovator or Analyst subscription via credit card (American Express, MasterCard, Visa) or SEPA Direct Debits. The larger team plans, API and enterprise solutions can be paid via invoicing and bank transfer.

 

Yes. We don’t serve ads, we never sell anything you give us, and we protect your privacy.